The United Nations Office at Geneva
Multimedia Newsroom
STORYLINE
Injectable HIV medicines deal to provide access to generic lifesaver in developing nations
A landmark agreement has been reached allowing for the production of low-cost, injectable HIV medicines in some 90 developing countries where more the majority of infections occur, UNITAID said on Friday.
Selected manufacturers will be able to develop, manufacture and supply lower-cost generic versions of long-acting Cabotegravir (CAB-LA), in line with a deal reached with pharmaceutical firm ViiV Healthcare (ViiV).
“The Medicines Patent Pool, a structure created and largely funded by UNITAID, has reached a voluntary licensing agreement for patents relating to Cabotegravir long-acting, an injectable form of HIV prevention, or PrEP, to generic formulations of the product in least-developed, low-income, lower-middle income and sub-Saharan African countries,” said UNITAID spokesperson Hervé Verhoosel.
The deal is significant because Cabotegravir injections are only needed once every few months. Increasing its supply at a cost that is affordable to low-income countries could help to overcome the stigma that’s associated with taking daily HIV pills - and the burden of having to remember to take them.
“In the 90 countries that we are talking about, 80 countries are royalty-free, meaning that ViiV won’t ask for any royalty on the product and for 10 of those countries, ViiV is asking for a smaller-than-usual royalty,” Mr. Verhoosel explained.
The agreement comes after UNITAID-led discussions began in May this year with ViiV, a subsidiary of pharma giant GlaxoSmithkline. It is only seven months since Cabotegravir LA received regulatory approval.
But the process of selecting the companies that will develop, manufacture and supply generic versions of Cabotegravir will take much longer.
“This product will not be there for everybody, that’s first for people who are there the most at risk,” said Mr. Verhoosel, who noted that the cost of the medicine in the US when it comes onstream there “really soon”, was likely to be around $20,000. “That’s a lot of money; that’s why that product cannot be used in low and middle-income countries.”
According to UNITAID, the deal offers the possibility of making the injectable prophylactic medicine available in 90 countries where more than 70 per cent of all new HIV infections occurred in 2020.
Up to three drug manufacturers will be licensed to develop the product on a generic basis to avoid supply and distribution issues. “That’s done in a way that we’re sure (that) one, it’s easy for logistics, two…availability, and three, of course, that it will help to bring the cost of the generic version down”, said Mr. Verhoosel.
ends
STORY: Injectable HIV Prevention Medicines Deal - UNITAID
TRT: 02’05”
SOURCE: UNTV CH
RESTRICTIONS: NONE
LANGUAGE: ENGLISH/NATS
ASPECT RATIO: 16:9
DATELINE: Friday 29 July 2022, GENEVA, SWITZERLAND
SHOTLIST
- Medium shot, UN Geneva flag alley.
- Wide shot, press room with panel of speakers, journalists, TV camera on tripod.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “The Medicines Patent Pool, a structure created and largely funded by UNITAID, has reached a voluntary licensing agreement for patents relating to cabotegravir long-acting, an injectable form of HIV prevention, or PrEP, to generic formulations of the product in least-developed, low-income, lower-middle income and sub-Saharan African countries.”
- Medium shot, lateral, podium speakers.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “In the 90 countries that we are talking about, 80 countries are royalty-free, meaning that ViiV (ViiV Healthcare) don’t ask any royalty on the product and for 10 of those countries ViiV is asking for a smaller-than-usual royalty.”
- Wide shot, journalists, TV camera, light panel.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “This product will not be there for everybody, that’s first for people who are there the most at risk. That’s a product that’s available in the US, and the price of that product for one year in the US for example is approximately 20,000 US dollars, and that’s a lot of money; that’s why that product cannot be used in low and middle-income countries.”
- Medium shot, journalists seated at tables, TV camera.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “This licence will actually give the option to three different generic manufacturers to develop the product on a generic base. That means that the price that those companies will have we don’t know yet, but that will not only be one company, that will be three different companies and that’s done in a way that we’re sure one, that it’s easy for logistics, two, that ensuring availability, and three, of course, that it will help to bring the cost of the generic version down.”
- Medium shot, journalists.
- Wide shot, journalists, TV camera and light panel.
- Medium shot, journalist.
- Medium shot, journalists, side shot.
Similar Stories
1
1
1
Edited News | UNICEF
Gaza: Thirsty and starving, war-battered families face ‘inhumane’ evacuation
As bombs continue to fall on Gaza City as part of the intensifying Israeli military operation, families with starving children are being pushed southwards from one “hellscape” to another, the UN Children’s Fund (UNICEF) said on Tuesday.
1
1
1
Edited News | OHCHR , UNOG
New UN Human Rights report finds 10 years of increased suffering repression and fear
The UN Human Rights Office on Friday published a report on the human rights situation in the Democratic People's Republic of Korea (DPRK) since 2014.
1
1
2
Edited News | UNICEF , UNHCR
The ongoing humanitarian response to the devastating Afghanistan earthquake disaster continued on Friday, although essential services have been cut for operational reasons following reinforced Taliban restrictions on women working with the UN, the global body said.
1
1
1
Edited News | OHCHR , UNOG
Un nouveau rapport du Haut-Commissariat des Nations Unies aux droits de l'homme sur la République démocratique du Congo évoque le spectre de crimes de guerre et de crimes contre l'humanité dans le Nord et le Sud-Kivu.,
2
1
2
Press Conferences , Edited News | HRC
A high-level independent rights probe into the Sudan crisis on Tuesday condemned the many grave crimes committed against civilians by all parties to the war, citing disturbing evidence indicating that they had been “deliberately targeted, displaced and starved”.
1
1
1
Edited News | WHO
Ukraine: ‘Relentless’ attacks rattle health system as winter approaches: WHO
Ambulances attacked, chronically ill patients lacking care and no peace in sight: for millions of Ukrainians, the run-up to another winter of war is just the latest life-or-death challenge they face, the UN health agency (WHO) said on Tuesday.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk on Monday delivered his report on Sri Lanka to the 60th session of the Human Rights Council in Geneva.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk on Monday delivered his global update to the 60th session of the Human Rights Council in Geneva.
1
1
1
Edited News | OHCHR
A UN report on the Democratic Republic of Congo raises specter of war crimes and crimes against humanity in North and South Kivu, according to UN Human Rights Spokesperson Ravina Shamdasani.
1
1
1
Edited News | WMO
As billions of people continue to breathe polluted air that causes more than 4.5 million premature deaths every year, UN climate experts on Friday highlighted how damaging microscopic smoke particles from wildfires play their part, travelling half-way across the world.
1
1
1
Edited News | OHCHR
UN Human Rights Office Spokesperson Jeremy Laurence made the following comment on the on-going presidential election process in Cameroon at the bi-weekly press briefing in Geneva.
1
1
1
Edited News | OHCHR
The UN Human Rights Office released a new report on Myanmar, describing death, destruction and desperation which reflect atrocities committed in 2017.